| symbol |
FOMx |
|---|
| 会社名 | Foamix Pharmaceuticals Ltd. （フォ―ミックス・ファ―マシュ―ティカルズ） |
|---|
| 分野（sector） |
Consumer Durables
耐久消費財
|
|---|
| 産業（industry） |
Specialty Chemicals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations using its technology which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne rosacea and other skin conditions. Its product candidates include FMX101 FMX102 FMX103 and FDX104. Its lead product candidate FMX101 is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101 FMX102 FMX103 and FDX104. フォ―ミックス・ファ―マシュ―ティカルズは、イスラエルの特殊医薬品会社。にきび、膿痂疹および他の皮膚疾患の治療用にミノサイクリンフォ―ムの開発、商品化を手掛ける。製品候補として、ミノサイクリンフォ―ム4％配合の中等度から重度のにきび用FMX101、ミノサイクリンフォ―ム1％配合の膿痂疹用FMX102の開発を行う。 Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.
|
|---|
| 本社所在地 | 2 Holzman St. Weizmann Science Park Rehovot 7670402 ISR |
|---|
| 代表者氏名 | ― |
|---|
| 代表者役職名 | ― |
|---|
| 電話番号 | +972 8-931-6233 |
|---|
| 設立年月日 | 37622 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2014年 |
|---|
| 従業員数 | 75人 |
|---|
| url | www.foamix.co.il |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/fomx |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -78.66200 |
|---|
| 終値（lastsale） | 4.98 |
|---|
| 時価総額（marketcap） | 203330033.52 |
|---|
| 時価総額 | 時価総額（百万ドル） 269.84650 |
|---|
| 売上高 | 売上高（百万ドル） 3.81400 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 215.68150 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -79.54900 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Foamix Pharmaceuticals Ltd revenues increased 8% to $1.9M. Net loss increased 45% to $44.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 49% to $39.7M (expense) Selling general and administrative increase of 7% to $6.7M (expense) Financial Expense. |
|---|